Efficacy and Safety of SUVN-N9503012, A Selective 5-HT1A Partial Agonist For the Symptomatic Treatment of Neurodegenerative Disorders.

Behavioral and psychological symptoms of dementia involve disturbed perception, mood disturbances, behavior changes, and thought content, leading to institutional care. While antipsychotics are prescribed, long-term use of these drugs is associated with an increased risk of mortality and an increased frequency of cerebrovascular events. The hippocampus, which plays a central role in cognition, is characterized by a high concentration of serotonin (5-hydroxytryptamine; 5-HT) 1A receptor binding sites. The 5-HT1A receptors have been implicated in various neuropsychiatric illnesses such as depression and anxiety. In the current research, we describe the profile of one of our lead compounds. SUVN-N9503012 is a potent and selective 5-HT1A receptor partial agonist being developed for the potential treatment of neurodegenerative diseases.